Gut and Endometrial Microbiome Dysbiosis: A New Emergent Risk Factor for Endometrial Cancer

• Main Authors: Soukaina Boutriq, Alicia González-González, Isaac Plaza-Andrades, Aurora Laborda-Illanes, Lidia Sánchez-Alcoholado, Jesús Peralta-Linero, María Emilia Domínguez-Recio, María José Bermejo-Pérez, Rocío Lavado-Valenzuela, Emilio Alba, María Isabel Queipo-Ortuño
• Format: Article
• Language: English
• Published: MDPI AG 2021-07-01
• Series: Journal of Personalized Medicine
• Subjects: endometrial cancer; endometrial microbiome; gut microbiome; dysbiosis; estrogen metabolism; estrobolome
• Online Access: https://www.mdpi.com/2075-4426/11/7/659

Endometrial cancer is one of the most common gynaecological malignancies worldwide. Histologically, two types of endometrial cancer with morphological and molecular differences and also therapeutic implications have been identified. Type I endometrial cancer has an endometrioid morphology and is estrogen-dependent, while Type II appears with non-endometrioid differentiation and follows an estrogen-unrelated pathway. Understanding the molecular biology and genetics of endometrial cancer is crucial for its prognosis and the development of novel therapies for its treatment. However, until now, scant attention has been paid to environmental components like the microbiome. Recently, due to emerging evidence that the uterus is not a sterile cavity, some studies have begun to investigate the composition of the endometrial microbiome and its role in endometrial cancer. In this review, we summarize the current state of this line of investigation, focusing on the relationship between gut and endometrial microbiome and inflammation, estrogen metabolism, and different endometrial cancer therapies.